Role Reversal: Millions of Kids Are Caregivers for Elders. Why Their Numbers Might Grow.
ST. PAUL, Minn. — High school senior Joshua Yang understands sacrifice. When he was midway…
Role Reversal: Millions of Kids Are Caregivers for Elders. Why Their Numbers Might Grow.
ST. PAUL, Minn. — High school senior Joshua Yang understands sacrifice. When he was midway through 10th grade, his mom survived a terrible car crash. But her body developed tremors, and she lost mobility. After countless appointments, doctors diagnosed her with Parkinson’s disease, saying it was likely triggered by brain injuries sustained in the wreck….
RFK Jr. Says Healthy Pregnant Women Don’t Need Covid Boosters. What the Science Says.
You’re pregnant, healthy, and hearing mixed messages: Health and Human Services Secretary Robert F. Kennedy Jr., who is not a scientist or doctor, says you don’t need the covid vaccine, but experts at the Centers for Disease Control and Protection still put you in a high-risk group of people who ought to receive boosters. The…
Allina Health Sees Early Success From Voice AI in Call Centers
About six months after rolling out voice AI in its call centers, Allina Health is already seeing signs that the tool is doing a good job of improving the patient experience. The technology is reducing patients’ average call times by 5-10 seconds, and 80% of calls are now answered in 45 seconds or less. The…
Allina Health Sees Early Success From Voice AI in Call Centers
About six months after rolling out voice AI in its call centers, Allina Health is already seeing signs that the tool is doing a good job of improving the patient experience. The technology is reducing patients’ average call times by 5-10 seconds, and 80% of calls are now answered in 45 seconds or less. The…
At ASCO, Merck KGaA Shows How Its Drug Measures Up as Treatment for Rare Type of Tumor
Merck KGaA’s pimicotinib led to statistically significant improvement on multiple measures of its Phase 3 test in tenosynovial giant cell tumor, positioning the drug to potentially compete with medications from Daiichi Sankyo and Ono Pharma. The Phase 3 results were presented during the annual meeting of the American Society of Clinical Oncology. The post At…
Analysis: The No Good, Very Bad Year for UnitedHealth
UnitedHealth Group has had a difficult year marked by a dramatic stock drop, leadership shake-up and mounting regulatory scrutiny. Experts point to its aggressive Medicare Advantage strategy and a rapidly evolving healthcare landscape as key drivers of its challenges. The post Analysis: The No Good, Very Bad Year for UnitedHealth appeared first on MedCity News.
A Call for Healthcare Cuts — But Not the Kind You’re Thinking Of
What if the kind of cuts we should be talking about are the ones that actually make care better? Like cutting confusion. Because for many people, the biggest barrier to healthcare access isn’t cost or availability – it’s complexity. The post A Call for Healthcare Cuts — But Not the Kind You’re Thinking Of appeared…
CMS’s Final Rule Impacting Star Ratings Puts Outcomes In Focus — Are Health Plans Ready to Take Action?
This is a great opportunity to align your strategies with CMS’s evolving framework by refining care models to focus on impact, investing in digital capabilities that support data use, and continuing to build infrastructure that addresses disparities in care. The post CMS’s Final Rule Impacting Star Ratings Puts Outcomes In Focus — Are Health Plans…
Journalists Draw Link Between Internet Dead Zones, Threatened Medicaid Cuts, and Health
Céline Gounder, KFF Health News’ editor-at-large for public health, discussed covid-19 vaccines and prostate cancer on WAMU’s “1A” on May 27. Click here to hear Gounder on “1A.” Senior correspondent Sarah Jane Tribble discussed how internet dead zones deepen chronic health issues in rural communities on The Commonwealth Fund’s “The Dose” on May 23. Click…
Astellas Stays Competitive in Hot Gut Cancer Target, Paying $130M to License Evopoint Drug
Astellas Pharma gets global rights to an Evopoint Biosciences antibody drug conjugate that targets Claudin 18.2. Last year, Astellas’s antibody drug Vyloy became the first FDA-approved therapy for this target. The post Astellas Stays Competitive in Hot Gut Cancer Target, Paying $130M to License Evopoint Drug appeared first on MedCity News.
